15% fall discount applied automatically at checkoutFree USA shipping over $100Free worldwide shipping over $200
Sign in 0

Tirzepatide 40mg

$249.99 or subscribe for $209.99/mo

Lot PL-2609-113 tested in our lab: 99.32% purity by HPLC Certificate PL-26-00113, analysed Sep 19, 2026 · LC-MS identity, endotoxin and sterility on the certificate · details and COA images
Third-party testing guarantee. Have this product tested by any independent laboratory. If the result does not come back as the compound named on the label, at the purity and amount stated, we refund your order in full and reimburse the cost of the test. Email the lab report and your order number to michael@prymalab.net.
Safety data sheet PL-SDS-173 GHS: Warning · H351, H361 · Read the SDS · PDF

Visa, Mastercard, Discover up to $1,000 per order (charged in MXN; your bank may add a foreign-transaction fee). Pay by Bank, Zelle, Cash App or crypto: 10% off.

Tirzepatide 40 mg: about 8.31 µmol of the acylated GIP and GLP-1 receptor agonist peptide, freeze-dried in a sealed vial. Every lot is tested in PrymaLab’s own laboratory and comes with a lot certificate. For research use only.

Description

PrymaLab · Research use only

Tirzepatide 40mg

Tirzepatide 40 mg, about 8.31 µmol of acylated peptide as freeze-dried powder

Tirzepatide is a 39-residue peptide agonist of the GIP and GLP-1 receptors, modified with a 20-carbon fatty diacid at lysine 20 and amidated at its C-terminus. This listing is a 40 mg vial of white lyophilized powder. Its literature includes structural work on how the peptide and its lipid side chain engage the two receptors.

Specifications

Tirzepatide 40mg at a glance
Property Value
Compound Tirzepatide LY3298176; GIP/GLP-1 receptor dual agonist
CAS number 2023788-19-2
Molecular formula C225H348N48O68
Theoretical mass 4813.5 Da
Sequence / structure H-Y-Aib-EGTFTSDYSI-Aib-LDKIAQK(2×AEEA-γGlu-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH₂ (39 residues; Aib2 and Aib13; Lys20 acylated with eicosanedioic acid via γ-Glu and two AEEA spacers; C-terminal amide)
Label claim 40 mg/vial
Form Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap
Storage, sealed −20 °C, desiccated, dark
Purity specification 99.0% or higher by RP-HPLC
Lot certificate Results for the lot now shipping are in the certificate panel on this page
Safety data sheet PL-SDS-173

Other fills

This is the 40 mg fill. The Tirzepatide 10mg page is the main listing for this compound, with the full research summary and every fill side by side. Other fills: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, 100 mg.

Molar figures for a 40 mg vial

At the theoretical mass of 4813.5 Da, 40 mg is about 8.31 µmol. Reconstituted in 1 mL that gives roughly 8.3 mM, in 2 mL about 4.2 mM and in 3 mL about 2.8 mM. Each is an upper bound, since the powder also holds residual water that the certificate measures by the Karl Fischer method. Working dilutions start from these stocks.

What the research covers

Sun and colleagues used cryogenic electron microscopy and molecular dynamics simulations to explain tirzepatide’s pharmacology at both receptors1. They showed how far the fatty acid modification, acting together with the amino acid sequence, decides the way a multireceptor agonist behaves1. On the certificate that modification is the eicosanedioic acid attached through γ-Glu and two AEEA spacers. Signalling and trial findings are on the Tirzepatide 10 mg main page.

The Retatrutide vs Tirzepatide guide covers the literature in more depth.

How each lot is tested

Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. The results for the lot now shipping are in the certificate panel on this page, and the certificate number, key and QR code can be checked on the verify page. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.

Frequently asked questions

Why quote the fill in micromoles?

Receptor and cell experiments are normally planned in molar units. Converting the label claim once, with the theoretical mass, lets a stock be made up in millimolar terms.

How can I tell the side chain is present?

Use the LC-MS identity result on the certificate. It is compared with the theoretical mass of the complete molecule, diacid and linker included, and a chain missing the side chain would read clearly lighter.

References

  1. Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. DOI · PubMed

Research use only

For laboratory research use only. Tirzepatide 40mg is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.

Additional information

Weight 0.1 lbs
Dimensions N/A

Lot PL-2609-113 · Certificate of Analysis PL-26-00113

Every lot is tested in our own laboratory before it ships. These are the reference facts for this compound and the results for the lot currently shipping. Open the certificate page to verify it by QR code or number.

CompoundTirzepatide
LY3298176; GIP/GLP-1 receptor dual agonist
CAS number2023788-19-2
Molecular formulaC225H348N48O68
Theoretical mass4813.5 Da
Sequence / structureH-Y-Aib-EGTFTSDYSI-Aib-LDKIAQK(2×AEEA-γGlu-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH₂ (39 residues; Aib2 and Aib13; Lys20 acylated with eicosanedioic acid via γ-Glu and two AEEA spacers; C-terminal amide)
AppearanceWhite lyophilized powder
Storage−20 °C, desiccated, dark
Label claim40 mg/vial
Lot numberPL-2609-113
Certificate numberPL-26-00113
Date of analysis2026-09-19 (retest 2028-09-18)
Purity (RP-HPLC)99.32%
Identity (LC-MS)4813.8 Da
Water content (KF)2.0%
Endotoxin (LAL)0.04 EU/mg
SterilityNo growth; conforms
ConclusionPASS
Tested byPrymaLab Analytical (PrymaLab's own laboratory, Ashland, KY). In-house result, not an independent third-party test.
Third-party testing guarantee. Have this product tested by any independent laboratory. If the result does not come back as the compound named on the label, at the purity and amount stated, we refund your order in full and reimburse the cost of the test. Email the lab report and your order number to michael@prymalab.net.
Certificate of analysis for lot PL-2609-113, page 1
Certificate page 1: results
Certificate of analysis for lot PL-2609-113, page 2
Certificate page 2: method and approval

Safety data sheet PL-SDS-173 · Tirzepatide

GHS safety data sheet for this product (lyophilized powder, vial), revision 1.0 of October 3, 2026. Read all 16 sections or download the PDF to keep with the material.

Warning
  • H351 Suspected of causing cancer.
  • H361 Suspected of damaging fertility or the unborn child.
CompositionTirzepatide (CAS 2023788-19-2) · ≥ 95% (dry basis, as supplied), 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg per vial
ClassificationCarcinogenicity (Category 2); Reproductive toxicity (Category 2)
Physical stateSolid. White to off-white lyophilized powder.
Storage−20 °C (sealed vial), desiccated and protected from light; 2–8 °C acceptable for short periods
HandlingOpen vials only in a clean area. Avoid generating or inhaling dust; weigh or reconstitute inside a ventilated enclosure when the full contents are handled as a dry powder. Reconstitute by adding diluent slowly to the vial wall; do not shake. Wash hands after handling.
First aidEyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice. Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice. Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
DisposalChemical waste through a licensed contractor; do not pour down the drain.
TransportNot regulated as a dangerous good (DOT / IATA / IMDG).

For laboratory research use only. Not for human or veterinary use.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Peptide Research Articles

How to reconstitute tirzepatide showing vial of lyophilized powder and bacteriostatic water for compounded tirzepatide mixing

How to Reconstitute Tirzepatide: Concentration and Storage

Tirzepatide is a 39-residue dual GIP and GLP-1 receptor agonist. This guide covers how the lyophilized peptide is dissolved and stored in the laboratory, how concentration is calculated and what the SURPASS and SURMOUNT trials measured.

24-hour support icon
24/7 Online support

support@prymalab.net info@prymalab.net

Quality guarantee badge icon
7-day returns

7-day returns on unopened, sealed products, plus our third-party testing guarantee.

Shipping truck icon
Free US shipping

Free USA shipping over $100 and free worldwide shipping over $200.

RealReviews.io Rate your experience with PrymaLab